Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Chemotherapy for BRCA-Mutated Prostate Cancer

November 27th 2018

PARP Inhibitors in Advanced Prostate Cancers

November 27th 2018

Genotyping in Prostate Cancer

November 27th 2018

Therapeutic Sequencing for CRPC Based on Recent Data

November 27th 2018

Earlier Detection of Prostate Cancer Bone Metastases

November 27th 2018

Assessment of Bone Health in Prostate Cancer

November 27th 2018

ERA 223 and Implications for Clinical Practice

November 27th 2018

Effect of Prostate Cancer Therapies on Bone Metabolism

November 27th 2018

Key Updates: Bone-Targeted Therapy for Metastatic CRPC

November 27th 2018

Bone Health in Prostate Cancer

November 27th 2018

Biochemical Prostate Cancer Recurrence Post Surgery/RT

November 27th 2018

Nonmetastatic CRPC: Does It Exist?

November 27th 2018

Defining Disease Volume in Metastatic Prostate Cancer

November 27th 2018

Radiotherapy for Oligometastatic Prostate Cancer

November 27th 2018

M0 Stage Prostate Cancer

November 27th 2018

Dose-Escalation Strategy Feasible With Novel Radionuclide Treatment in mCRPC

November 21st 2018

Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.

Surgery and Adjuvant RT Show Superiority in Locally Advanced Prostate Cancer

November 20th 2018

Higher survival rates were observed with radical prostatectomy and adjuvant radiotherapy compared with radiotherapy and androgen deprivation therapy in men with locally advanced prostate cancer.

Hypofractionated Radiation Recommended for Localized Prostate Cancer

November 20th 2018

A panel of experts has recommended hypofractionated radiation as an alternative to longer, conventional courses of radiation for men with earlystage prostate cancer who opt for external beam radiation therapy.

Dr. Morris Discusses PSMA-Targeted Imaging in mCRPC

November 20th 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the use of prostate-specific membrane antigen (PSMA)-targeted imaging in patients with metastatic castration-resistant prostate cancer.

EU Panel Backs Apalutamide in Nonmetastatic CRPC

November 19th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use granted support for approval of apalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease.